Drugs for Lip and Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 161)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
2 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
3 |
|
Dopexamine |
Approved, Investigational |
Phase 4 |
|
86197-47-9 |
55483 |
Synonyms:
Dopacard
DOPEXAMINE
Dopexamine dihydrobromide
Dopexamine dihydrochloride
|
Dopexamine hydrochloride
FPL 60278
FPL-60278
|
|
4 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(−)-noradrenaline
(-)-Noradrenaline
(−)-norepinephrine
(-)-Norepinephrine
(-)-norepinephrine|Levarterenol®|noradrenaline
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-norepinephrine
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]PYROCATECHOL
Adrenor
Aktamin
Arterenol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
|
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-Arterenol
Levarterenol
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
L-noradrenaline
L-Norepinephrine
Noradrenalin
Noradrenaline
Nor-adrenaline
Norartrinal
Norepinefrina
Norepinephrine
Norépinéphrine
Norepinephrinum
Norepirenamine
Nor-epirenan
R-NOREPINEPHRINE
Sympathin E
|
|
5 |
|
Dobutamine |
Approved |
Phase 4 |
|
34368-04-2 |
36811 |
Synonyms:
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-b-phenylethylamine
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
Boehringer ingelheim brand OF dobutamine hydrochloride
COMPOUND 81929
COMPOUND-81929
DL-Dobutamine
Dobucor
Dobuject
Dobutamin
Dobutamin fresenius
Dobutamin hexal
Dobutamin ratiopharm
Dobutamin solvay
Dobutamina
Dobutamina [INN-Spanish]
Dobutamina inibsa
Dobutamina rovi
Dobutamine
Dobutamine (+)-isomer
Dobutamine [Usan:Ban:Inn]
Dobutamine [Usan]
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine hydrobromide
Dobutamine hydrochloride
dobutamine hydrochloride|Dobutrex®|Inotrex®
Dobutamine lactobionate
Dobutamine phosphate (1:1) salt, (-)-isomer
|
Dobutamine tartrate
Dobutamine tartrate (1:1), (R-(r*,r*))-isomer
Dobutamine tartrate (1:1), (S-(r*,r*))-isomer
Dobutamine, (-)-isomer
Dobutamine, phosphate (1:1) salt (+)-isomer
Dobutamin-ratiopharm
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
Eli lilly brand OF dobutamine hydrochloride
Fresenius brand OF dobutamine hydrochloride
Hexal brand OF dobutamine hydrochloride
Hydrobromide, dobutamine
Hydrochloride, dobutamine
Inibsa brand OF dobutamine hydrochloride
Inotrex
Irisfarma brand OF dobutamine hydrochloride
Juste brand OF dobutamine hydrochloride
Kendrick brand OF dobutamine hydrochloride
Lactobionate, dobutamine
Lilly 81929
Lilly brand OF dobutamine hydrochloride
Oxiken
Pisa brand OF dobutamine hydrochloride
Posiject
rac-Dobutamine
Racemic-dobutamine
Ratiopharm brand OF dobutamine hydrochloride
Rovi brand OF dobutamine hydrochloride
Solvay brand OF dobutamine hydrochloride
Tartrate, dobutamine
|
|
6 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
7 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
8 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
9 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
10 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
11 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
12 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
13 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
15 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
16 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
17 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
18 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
19 |
|
Mydriatics |
|
Phase 4 |
|
|
|
20 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
21 |
|
Erlotinib |
Approved, Investigational |
Phase 3 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
22 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 3 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
23 |
|
Zinc sulfate |
Approved, Investigational |
Phase 3 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
24 |
|
Docetaxel |
Approved, Investigational |
Phase 2, Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
25 |
|
Carboplatin |
Approved |
Phase 2, Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
26 |
|
Atezolizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
27 |
|
Cetuximab |
Approved |
Phase 2, Phase 3 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
28 |
|
Durvalumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1428935-60-7 |
|
Synonyms:
|
29 |
|
Trace Elements |
|
Phase 3 |
|
|
|
30 |
|
Micronutrients |
|
Phase 3 |
|
|
|
31 |
|
Antimitotic Agents |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Tubulin Modulators |
|
Phase 2, Phase 3 |
|
|
|
33 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
34 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
35 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
36 |
|
Immunoglobulin G |
|
Phase 2, Phase 3 |
|
|
|
37 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Plasminogen |
Approved |
Phase 2 |
|
9001-91-6 |
|
Synonyms:
1-glutamylplasminogen
Human plasminogen
Plasma trypsinogen
|
plasminogen, human-tvmh
Profibrinolysin
|
|
40 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
41 |
|
Raspberry |
Approved |
Phase 1, Phase 2 |
|
|
|
42 |
|
Aminolevulinic acid |
Approved |
Phase 1, Phase 2 |
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
43 |
|
Orange |
Approved |
Phase 1, Phase 2 |
|
|
|
44 |
|
Hydroxyurea |
Approved |
Phase 1, Phase 2 |
|
127-07-1 |
3657 |
Synonyms:
Biosupressin
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroxyamic acid
Carbamoyl oxime
Carbamyl hydroxamate
Carbamyl hydroxamic acid
Droxia
Droxia®|Hydrea®|hydroxycarbamide|Siklos®|SQ-1089|Xromi®
Hidrix
Hidroxicarbamida
HU
Hydrea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
|
Hydroxycarbamine
Hydroxyharnstoff
Hydroxylurea
HYDROXYUREA
Hydura
Hydurea
Idrossicarbamide
Idrossicarbamide [Dcit]
Litaler
Litalir
N-Carbamoylhydroxylamine
N-HYDROXYUREA
NSC-32065
Oncocarbide
Onco-Carbide
Oxyurea
SIKLOS
SQ-1089
Sterile Urea
Ureaphil
|
|
45 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
46 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
47 |
|
Cemiplimab |
Approved, Investigational |
Phase 2 |
|
1801342-60-8 |
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
48 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
49 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
50 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
Interventional clinical trials:
(show top 50)
(show all 173)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial |
Unknown status |
NCT03684707 |
Phase 4 |
Metformin Hcl 500Mg 24Hr Sa Tab |
2 |
An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study |
Completed |
NCT01418118 |
Phase 4 |
Epinephrine;Norepinephrine;Dobutamine;Dopexamine |
3 |
The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor |
Recruiting |
NCT03017053 |
Phase 4 |
|
4 |
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) |
Unknown status |
NCT03685409 |
Phase 3 |
Metformin Hydrochloride 500 MG;Placebo Oral Tablet |
5 |
Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. |
Unknown status |
NCT00655421 |
Phase 3 |
|
6 |
Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS |
Unknown status |
NCT01039298 |
Phase 3 |
|
7 |
Workplace Tobacco Cessation And Oral Cancer Screening Study |
Completed |
NCT00750503 |
Phase 3 |
|
8 |
Erlotinib Prevention of Oral Cancer (EPOC) |
Completed |
NCT00402779 |
Phase 3 |
Erlotinib;Placebo |
9 |
Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158652 |
Phase 3 |
5FU, Paraplatin |
10 |
Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) |
Completed |
NCT00964977 |
Phase 3 |
|
11 |
Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158678 |
Phase 3 |
concomitant cisplatin |
12 |
A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00162708 |
Phase 2, Phase 3 |
CDDP, 5 Fu |
13 |
Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Completed |
NCT01434394 |
Phase 2, Phase 3 |
Neo-adjuvant Erbitux-based chemotherapy |
14 |
Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial |
Completed |
NCT03824925 |
Phase 3 |
Placebo oral Zinc capsule;Zinc Sulfate 220 MG |
15 |
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
Recruiting |
NCT05063552 |
Phase 2, Phase 3 |
Carboplatin;Cisplatin;Docetaxel |
16 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
Recruiting |
NCT04333537 |
Phase 2, Phase 3 |
Imaging Agent |
17 |
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin |
Active, not recruiting |
NCT03258554 |
Phase 2, Phase 3 |
|
18 |
Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial |
Not yet recruiting |
NCT05429099 |
Phase 2, Phase 3 |
|
19 |
Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) |
Terminated |
NCT00537199 |
Phase 3 |
OraTest |
20 |
Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer |
Unknown status |
NCT02960724 |
Phase 2 |
|
21 |
Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral |
Unknown status |
NCT03008694 |
Phase 2 |
|
22 |
Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer |
Unknown status |
NCT02739204 |
Phase 2 |
Celecoxib |
23 |
Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy |
Completed |
NCT04251949 |
Phase 2 |
|
24 |
A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) |
Completed |
NCT00933387 |
Phase 2 |
Cetuximab,Paclitaxel,Cisplatin |
25 |
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral |
Completed |
NCT03638622 |
Phase 1, Phase 2 |
|
26 |
Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) |
Completed |
NCT01733797 |
Phase 2 |
|
27 |
A Study of the Effects of PEITC on Oral Cells With Mutant p53 |
Completed |
NCT01790204 |
Phase 1, Phase 2 |
|
28 |
Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Completed |
NCT01440270 |
Phase 2 |
Neo-adjuvant Erbitux-based chemotherapy |
29 |
A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer |
Completed |
NCT00004901 |
Phase 1, Phase 2 |
ethynyluracil;fluorouracil;hydroxyurea |
30 |
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention |
Completed |
NCT01192204 |
Phase 1, Phase 2 |
10% FBR containing bioadhesive gel;placebo gel |
31 |
Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer |
Completed |
NCT01469429 |
Phase 1, Phase 2 |
chemoprevention |
32 |
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] |
Completed |
NCT00064103 |
Phase 1, Phase 2 |
|
33 |
Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial |
Completed |
NCT00330382 |
Phase 2 |
Bowman-Birk inhibitor concentrate |
34 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
35 |
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN) |
Recruiting |
NCT03383094 |
Phase 2 |
Pembrolizumab;Cisplatin |
36 |
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
NCT04862650 |
Phase 2 |
Carboplatin;Paclitaxel |
37 |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing |
Recruiting |
NCT02734537 |
Phase 2 |
Cisplatin |
38 |
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
Recruiting |
NCT05136196 |
Phase 2 |
Cabozantinib S-malate |
39 |
Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
NCT03174275 |
Phase 2 |
Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin |
40 |
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
NCT03529422 |
Phase 2 |
Durvalumab |
41 |
M4OC-Prevent: Metformin for Oral Cancer Prevention |
Active, not recruiting |
NCT02581137 |
Phase 2 |
Metformin Hydrochloride |
42 |
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin |
Active, not recruiting |
NCT04541355 |
Phase 2 |
Cisplatin;Sodium Thiosulfate |
43 |
Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging |
Not yet recruiting |
NCT04191460 |
Phase 2 |
cRGD-ZW800-1. |
44 |
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line |
Not yet recruiting |
NCT05456022 |
Phase 2 |
Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one;Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT);Doxorubicin chemotherapeutic drug as a positive control |
45 |
M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention |
Not yet recruiting |
NCT05237960 |
Phase 2 |
Extended Release Metformin Hydrochloride;Placebo Administration |
46 |
Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent |
Not yet recruiting |
NCT05316688 |
Phase 1, Phase 2 |
Tozuleristide |
47 |
Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints |
Terminated |
NCT00400205 |
Phase 2 |
Docetaxel;Cisplatin;5-fluorouracil |
48 |
Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions |
Completed |
NCT01604759 |
Phase 1 |
|
49 |
Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients |
Completed |
NCT02946671 |
Phase 1 |
|
50 |
Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer |
Completed |
NCT01445405 |
Phase 1 |
Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin |
|